Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Bendamustine and Melphalan in Myeloma
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 121
- Registration Number
- NCT03187223
- Locations
- 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 43
- Registration Number
- NCT03159702
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Auto Stem Cell Transplant for Lymphoma Patients
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 150
- Registration Number
- NCT03125642
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT03118492
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03100877
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeLangerhans Cell HistiocytosisAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaNon-Hodgkin LymphomaRecurrent Hodgkin LymphomaTherapy-Related Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03096782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03073694
- Locations
- 🇺🇸
The University of Kansas Medical Center, Westwood, Kansas, United States
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT03072771
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT03061656
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03019640
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.